Assembly Biosciences develops antiviral medicines for serious viral diseases, including genital herpes and hepatitis. ASMB reports earnings on Mon, Nov 9, 2026.
Prices, price targets and earnings estimates for ASMB are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in ASMB in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ASMB is in one of them and how their past ASMB trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Assembly Biosciences
Assembly Biosciences is a biotechnology company based in South San Francisco, California, that develops antiviral medicines for people with serious viral diseases. Its experimental treatments target genital herpes, hepatitis delta, hepatitis B and herpesviruses that can affect transplant patients. Gilead Sciences has licensed its genital herpes program, and the company is seeking partners for its hepatitis B candidate. Its other programs remain in clinical testing or early research.
